P2X7 — P2X Purinoceptor 7

Migration, Crosslink

📖

P2X7 — P2X Purinoceptor 7

active

wiki page Created: 2026-04-02T07:19:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-p2x7

📖 Wiki Page

protein1675 wordssynced 2026-04-02

P2X7 — P2X Purinoceptor 7

Pathway Diagram

flowchart TD P2X7["P2X7"] style P2X7 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0 NLRP3_Inflammasome["NLRP3 Inflammasome"] P2X7 -->|"activates"| NLRP3_Inflammasome Apoptosis["Apoptosis"] P2X7 -->|"activates"| Apoptosis ATP["ATP"] P2X7 -->|"expressed in"| ATP Als["Als"] P2X7 -->|"associated with"| Als Ms["Ms"] P2X7 -->|"associated with"| Ms Diabetes["Diabetes"] P2X7 -->|"associated with"| Diabetes Aging["Aging"] P2X7 -->|"expressed in"| Aging P2X7 -->|"activates"| Ms Extracellular_ATP["Extracellular ATP"] Extracellular_ATP -->|"binds"| P2X7 APOPTOSIS["APOPTOSIS"] APOPTOSIS -->|"activates"| P2X7 style NLRP3_Inflammasome fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0 style Apoptosis fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0 style ATP fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0 style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Ms fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Diabetes fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Aging fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Extracellular_ATP fill:#006494,stroke:#4fc3f7,color:#e0e0e0 style APOPTOSIS fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0

Overview

...

P2X7 — P2X Purinoceptor 7

Pathway Diagram

Mermaid diagram (expand to render)

Overview

P2X7 (P2X receptor 7) is an ATP-gated ion channel encoded by the P2RX7 gene located on chromosome 12q24.31. It plays a critical role in neuroinflammation and is implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and other neurodegenerative disorders. Unlike other P2X receptors, P2X7 exhibits unique pharmacological and functional properties that make it a compelling therapeutic target.

The P2X7 receptor is primarily expressed on immune cells, particularly [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system, where it functions as a sentinel for extracellular ATP released during cellular stress, tissue damage, or pathological conditions. Activation of P2X7 triggers a cascade of pro-inflammatory events that, when chronic, contribute to neurotoxicity and disease progression. [@receptor2020]

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">P2X7 Receptor</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>P2RX7</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>12q24.31</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>10029</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>Q99572</td></tr>
<tr><td><strong>Protein Length</strong></td><td>595 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~66 kDa (monomer), ~200 kDa (trimer)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>P2X receptor family (ligand-gated ion channels)</td></tr>
<tr><td><strong>Ligand</strong></td><td>Extracellular ATP (EC₅₀ ~100-300 μM)</td></tr>
<tr><td><strong>Expression</strong></td><td>High: microglia. Moderate: astrocytes, neurons</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">89 edges</a></td>
</tr>
</table>
</div>

Gene and Protein Structure

P2RX7 Gene Organization

The P2RX7 gene spans approximately 54 kb and consists of 17 exons. Multiple alternatively spliced isoforms have been identified, including variants with altered trafficking or function. Single nucleotide polymorphisms (SNPs) in P2RX7 have been extensively studied for their association with inflammatory and neurodegenerative diseases. [@sevigny2017]

Protein Architecture

P2X7 is a trimeric ligand-gated ion channel with a unique structure:

Extracellular Domain (~280 aa): Contains the ATP-binding site with conserved glutamate residues critical for ligand recognition. The extracellular loop contains multiple cysteine residues forming disulfide bonds that stabilize the structure.

Transmembrane Domains (TM1, TM2): Two α-helical transmembrane segments that form the channel pore. TM2 contains a hydrophobic segment that lines the ion channel.

Intracellular N- and C-termini: The C-terminal tail (~220 aa) is critical for channel function, containing motifs for:

Protein-protein interactions
Phosphorylation sites
Palmitoylation sites
Interaction with the actin cytoskeleton

The P2X7 receptor exhibits a distinctive "pannexin-1 hemichannel" mode of signaling where prolonged ATP activation leads to formation of a large pore capable of passing molecules up to 900 Da, independent of the ion channel function.

Normal Physiological Functions

ATP Signaling and Purinergic Signaling

Under physiological conditions, extracellular ATP concentrations are maintained at nanomolar levels through the coordinated action of ectonucleotidases (CD39, CD73) and ATP-release mechanisms. P2X7 acts as a danger sensor, responding to the ATP surge that occurs during:

Cellular stress or injury
Pathogen invasion
Tissue damage
Inflammation

The receptor exhibits low affinity for ATP (EC₅₀ ~100-300 μM), meaning it requirespathological ATP release to activate, distinguishing it from other P2X receptors that respond to physiological ATP concentrations.

Immune Cell Activation

In immune cells, P2X7 activation triggers:

NLRP3 inflammasome assembly: P2X7 activation provides signal 1 (priming) and signal 2 (activation) for NLRP3 inflammasome formation [@nlrp2020]
IL-1β processing and release: Pro-IL-1β is cleaved by caspase-1 activated through NLRP3 inflammasome signaling
Pyroptosis: In some contexts, P2X7 activation triggers gasdermin D-mediated pyroptotic cell death
Phospholipid scrambling: Activation leads to phosphatidylserine exposure on cell surfaces

Tissue Homeostasis

In non-neuronal tissues, P2X7 participates in:

Wound healing and tissue repair
Immune surveillance
Cell proliferation and differentiation
Bone remodeling

Role in Neuroinflammation

P2X7 is centrally positioned at the intersection of ATP release, microglial activation, and neuroinflammation. In the CNS, microglia express high levels of P2X7 and serve as the primary responders to extracellular ATP released from damaged [neurons](/entities/neurons), activated astrocytes, or themselves. [@neuroinflammation2019]

Microglial Activation

P2X7 on microglia mediates:

Morphological transformation: From ramified resting to amoeboid activated state

Cytokine production: IL-1β, IL-6, TNF-α, IL-18

Chemokine production: CCL2, CXCL10

Reactive oxygen species (ROS) production: Through NADPH oxidase activation

Nitric oxide (NO) production: Via inducible nitric oxide synthase (iNOS)

Phagocytosis modulation: Enhanced phagocytic activity in early stages

Astrocyte-Neuron Communication

P2X7 on astrocytes responds to neuronal ATP release and:

Modulates astrocyte reactivity
Regulates glutamate uptake and release
Influences blood-brain barrier integrity
Coordinates neuroinflammatory responses

Role in Alzheimer's Disease

In Alzheimer's disease (AD), P2X7 contributes to multiple pathological processes:

Amyloid-beta and P2X7

Elevated P2X7 expression in [microglia](/cell-types/microglia-neuroinflammation) surrounding amyloid plaques [@receptor2020]
Aβ peptides directly activate P2X7 through ATP release from cells
P2X7 activation promotes further amyloidogenic APP processing
Genetic variants in P2RX7 associated with increased AD risk

Tau Pathology and P2X7

P2X7 influences [tau](/proteins/tau) pathology through:

NLRP3 inflammasome activation leading to increased tau phosphorylation
IL-1β release promoting tau pathology spread
Regulation of tau secretion and propagation [@riquelme2021]

Synaptic Dysfunction

P2X7 activation contributes to synaptic loss
Promotes excessive glutamate release from glia
Contributes to excitotoxicity through dysregulated calcium signaling
Impairs synaptic plasticity mechanisms

Therapeutic Implications for AD

P2X7 antagonists show promise in AD models:

Brilliant Blue G (BBG) reduces amyloid plaque burden
A-438079 improves cognitive function in AD mice
P2X7 deletion protects against Aβ-induced memory deficits
Combined anti-inflammatory and anti-amyloid approaches

Role in Parkinson's Disease

In Parkinson's disease (PD), P2X7 plays a critical role in dopaminergic neuron degeneration: [@parkinsons2021]

Microglial Activation in Substantia Nigra

P2X7 highly expressed in substantia nigra microglia
ATP released from damaged dopaminergic [neurons](/cell-types/dopaminergic-neurons) triggers microglial activation
Chronic P2X7 activation leads to neurotoxic phenotype
P2X7 blockade protects dopaminergic neurons [@martinez2020]

Alpha-synuclein and P2X7

P2X7 interacts with [alpha-synuclein](/proteins/alpha-synuclein) pathology:

P2X7 activation promotes α-synuclein aggregation
α-Synuclein can activate P2X7 on microglia
NLRP3 inflammasome links α-synuclein to neuroinflammation
P2X7 antagonism reduces α-synuclein pathology in models [@yang2022]

Mitochondrial Dysfunction

P2X7 activation contributes to mitochondrial dysfunction
Loss of mitochondrial membrane potential
Increased ROS production
Impaired mitophagy

Therapeutic Strategies for PD

P2X7-targeted approaches:

BBG protects dopaminergic neurons in MPTP models
P2X7 knockout mice resistant to MPTP toxicity
Antagonists reduce microglial activation and rescue neurons
Blood-brain barrier penetration remains a challenge

Role in Amyotrophic Lateral Sclerosis

In ALS, P2X7 contributes to motor neuron degeneration: [@chen2020]

Microglial P2X7 in ALS

Upregulated P2X7 in ALS microglia
Activated microglia release toxic factors
P2X7-mediated inflammation accelerates motor neuron death
Genetic variants affect ALS susceptibility

TDP-43 Pathology

P2X7 interacts with TDP-43 proteinopathy
NLRP3 inflammasome activation in ALS
Links between RNA metabolism and inflammation

Therapeutic Targeting in ALS

P2X7 antagonists protect motor neurons
Combined approaches targeting multiple pathways
Early intervention may be critical

Role in Multiple Sclerosis

P2X7 is implicated in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE): [@engelhardt2022]

P2X7 expressed on infiltrating immune cells
Promotes myelin-specific T cell activation
Contributes to demyelination
P2X7 blockade ameliorates EAE

Autophagy and P2X7

P2X7 regulates [autophagy](/mechanisms/autophagy), a critical process in neurodegeneration: [@he2021]

P2X7 activation modulates autophagy flux
Dysregulated autophagy contributes to protein aggregation
P2X7-NLRP3 axis affects mitophagy
Therapeutic modulation of autophagy shows promise

Expression Pattern in the Brain

| Cell Type | Expression Level | Key Functions |
|-----------|------------------|---------------|
| Microglia | High | Primary immune sensor, inflammasome activation |
| Astrocytes | Moderate | Neuroinflammation coordination |
| Neurons | Low-Moderate | ATP sensing, calcium signaling |
| Oligodendrocytes | Low | Myelin maintenance |

Therapeutic Targeting

P2X7 Antagonists

Several P2X7 antagonists have been developed:

| Compound | Specificity | Stage | Notes |
|----------|--------------|-------|-------|
| Brilliant Blue G (BBG) | Non-selective | Preclinical | FDA-approved for some uses, BBB penetration |
| A-438079 | Selective | Preclinical | Anti-inflammatory effects |
| A-740003 | Selective | Preclinical | Neuroprotective in models |
| AZD9056 | Selective | Clinical trials | Tested for inflammatory diseases |
| CE-224535 | Selective | Clinical trials | Rheumatoid arthritis |

Challenges in CNS Drug Development

Blood-brain barrier penetration: Many P2X7 antagonists do not cross the BBB
Peripheral vs. central effects: Distinguishing central vs. peripheral P2X7 actions
Dosing: Chronic dosing required for neurodegenerative diseases
Safety: Immune suppression concerns with long-term use

Emerging Approaches

Brain-penetrant antagonists: New molecules with improved BBB penetration
Allosteric modulators: Targeting distinct binding sites
Nanoparticle delivery: Targeted CNS delivery
Gene therapy: Viral vector-mediated delivery

Genetic Variants and Disease Risk

P2RX7 polymorphisms have been associated with:

Alzheimer's disease: Multiple SNPs affect risk
Parkinson's disease: Some variants increase susceptibility
Multiple sclerosis: Genetic associations identified
Inflammatory disorders: Rheumatoid arthritis, Crohn's disease

These genetic findings support P2X7 as a therapeutic target.

Diagnostic and Biomarker Potential

P2X7 expression may serve as biomarker for neuroinflammation
PET ligands for P2X7 in development
Cerebrospinal fluid IL-1β as downstream marker
Peripheral blood monocyte P2X7 as accessible marker

[NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
[Microglia](/cell-types/microglia-neuroinflammation)
[IL-1β](/proteins/il1b-protein)
[Alpha-synuclein](/proteins/alpha-synuclein)
[Tau Protein](/proteins/tau)
[Amyloid-beta](/proteins/amyloid-beta)
[NF-κB Signaling](/mechanisms/nf-kb-signaling)
[Autophagy](/mechanisms/autophagy)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/als)

Key Publications

[P2X7 receptor in Alzheimer's disease (2020)](https://doi.org/10.1016/j.neuropharm.2020.108123)

[P2X7 and neuroinflammation (2019)](https://doi.org/10.1111/jnc.14738)

[P2X7 in Parkinson's disease (2021)](https://doi.org/10.1007/s00401-021-02276-3)

[NLRP3 inflammasome and P2X7 signaling (2020)](https://doi.org/10.1016/j.tips.2020.03.008)

[P2X7 as therapeutic target in neurodegeneration (2022)](https://doi.org/10.1016/j.pharmthera.2022.108267)

[P2X7 receptor: a new neuroprotective target (2015)](https://pubmed.ncbi.nlm.nih.gov/26149747/)

[P2X7 in multiple sclerosis (2022)](https://pubmed.ncbi.nlm.nih.gov/35193345/)

[The P2X7 receptor in extracellular ATP signaling (2017)](https://pubmed.ncbi.nlm.nih.gov/28632473/)

[Brilliant Blue G as P2X7 antagonist (2021)](https://pubmed.ncbi.nlm.nih.gov/33445567/)

[P2X7 and α-synuclein in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

References

[P2X7 receptor in Alzheimer's disease, Neuropharmacology (2020)](https://doi.org/10.1016/j.neuropharm.2020.108123)

[P2X7 and neuroinflammation, J Neurochem (2019)](https://doi.org/10.1111/jnc.14738)

[P2X7 in Parkinson's disease, Acta Neuropathol (2021)](https://doi.org/10.1007/s00401-021-02276-3)

[NLRP3 inflammasome and P2X7 signaling, Trends Pharmacol Sci (2020)](https://doi.org/10.1016/j.tips.2020.03.008)

[P2X7 as therapeutic target in neurodegeneration, Pharmacol Ther (2022)](https://doi.org/10.1016/j.pharmthera.2022.108267)

[P2X7 receptor: a new neuroprotective target, Front Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/26149747/)

[P2X7 in multiple sclerosis, J Neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35193345/)

[The P2X7 receptor joins the extracellular ATP signaling network, Pflugers Arch (2017)](https://pubmed.ncbi.nlm.nih.gov/28632473/)

[Brilliant Blue G as P2X7 antagonist, Front Cell Neurosci (2021)](https://pubmed.ncbi.nlm.nih.gov/33445567/)

[P2X7 and α-synuclein interplay, J Parkinsons Dis (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

External Links

[NCBI Gene: P2RX7](https://www.ncbi.nlm.nih.gov/gene/10029)
[UniProt: Q99572](https://www.uniprot.org/uniprot/Q99572)
[IUPHAR Database: P2X7](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=442)
[KEGG Pathway: P2X7 signaling](https://www.genome.jp/kegg/pathway.html)

Pathway Diagram

The following diagram shows the key molecular relationships involving P2X7 — P2X Purinoceptor 7 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

P2X7

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-p2x7
kg_node_id	P2X7
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-058f49a7f977
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-p2x7'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

41

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

P2X7 — P2X Purinoceptor 7

P2X7 — P2X Purinoceptor 7

Pathway Diagram

Overview

P2X7 — P2X Purinoceptor 7

Pathway Diagram

Overview

Gene and Protein Structure

P2RX7 Gene Organization

Protein Architecture

Normal Physiological Functions

ATP Signaling and Purinergic Signaling

Immune Cell Activation

Tissue Homeostasis

Role in Neuroinflammation

Microglial Activation

Astrocyte-Neuron Communication

Role in Alzheimer's Disease

Amyloid-beta and P2X7

Tau Pathology and P2X7

Synaptic Dysfunction

Therapeutic Implications for AD

Role in Parkinson's Disease

Microglial Activation in Substantia Nigra

Alpha-synuclein and P2X7

Mitochondrial Dysfunction

Therapeutic Strategies for PD

Role in Amyotrophic Lateral Sclerosis

Microglial P2X7 in ALS

TDP-43 Pathology

Therapeutic Targeting in ALS

Role in Multiple Sclerosis

Autophagy and P2X7

Expression Pattern in the Brain

Therapeutic Targeting

P2X7 Antagonists

Challenges in CNS Drug Development

Emerging Approaches

Genetic Variants and Disease Risk

Diagnostic and Biomarker Potential

Cross-Links to Related Entities

Key Publications

References

See Also

External Links

Pathway Diagram

💬 Discussion